Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants inc...
Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5
About this item
Full title
Author / Creator
Publisher
London: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
On Aug 9, 2023, WHO classified EG.5 as a variant of interest.3 In fact, our epidemic dynamics analyses showed that EG.5.1 exhibits a higher effective reproduction number (Re) compared with XBB.1.5, XBB.1.16, and its parental lineage (XBB.1.9.2), suggesting that EG.5.1 will spread globally and outcompete these XBB subvariants in the near future (app...
Alternative Titles
Full title
Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2865788747
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2865788747
Other Identifiers
ISSN
1473-3099,1474-4457
E-ISSN
1474-4457
DOI
10.1016/S1473-3099(23)00553-4
